On May 5, 2026, Exelixis management expressed confidence in their financial trajectory, with CEO Michael Morrissey touting a strong start to the year and CFO Christopher Senner explicitly reiterating full-year guidance. However, following the release of second-quarter results that fell below Wall Street consensus with revenue of approximately $628.7 million, the company abruptly lowered its outlook. The firm attributed this reversal to a slower-than-expected commercial ramp for its neuroendocrine-tumor business.

Legal investigators are now scrutinizing whether leadership was aware of these mounting performance hurdles before they reaffirmed their financial targets to the market. The inquiry focuses on whether investors purchased shares at artificially inflated prices based on potentially inaccurate statements. Shareholders who sustained losses during this period are currently being encouraged to provide trade documentation for an evaluation of potential claims. The investigation is being managed on a contingency basis, meaning there are no upfront costs for participants.